Meta-Analysis Quantifies Toxicity Profile of Fruquintinib in GI Malignancies

▸ TREATMENT

A systematic review and meta-analysis of phase II–III randomized trials synthesized evidence on the incidence and relative risk of key toxicities associated with fruquintinib, a VEGFR inhibitor approved for metastatic colorectal cancer. (Oncology Research)